from an independent advisory panel, has the potential to explode the federal budget and move an already simmering debate over drug prices in Congress and the White House onto the front burner.
Medicare patients without additional insurance would also be on the hook for up to 20 percent of the cost of their treatment, about $11,500 per year. And premiums could spike for supplemental plans that cover the treatment.resigned in protest, “It’s in many ways a version of other drug pricing and FDA debates we’ve had over the last several years, but it turns the knobs up to 10,” said Rachel Sachs, a law professor at Washington University in St. Louis who researches health policy.
The business of medicine, has got us by the short hairs.
In America, when dying slowly and miserably makes more money than the alternative, you're gonna die slowly and miserably.
This is a new cheap ass drug that helps replay the last twenty years not a good drug to fight Alzheimer's by giving them a twenty year future outlook. Stopp looking behind and look forward
samgandy Thank you the great article, but Aduhelm is not an 'Alzheimer's drug.' Should be, and many people think it is, given FDA approval, but it just isn't.
Drug companies take donated money and tax dollars for research then keep all the profits from the drug .... Seems legit
🤦♂️🤦♂️🤦♂️
🤦♂️🤦♂️🤦♂️
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TMZ - 🏆 379. / 59 Read more »
Source: latimes - 🏆 11. / 82 Read more »
Source: Forbes - 🏆 394. / 53 Read more »